Leveraging TCR-Based & TCR-Mimetic Bispecifics to Overcome Specificity & Density Challenges in Solid Tumours
- Unlocking high tumour specificity with TCR-based bispecifics – exploring how targeting peptide–HLA complexes enables precision beyond surface tumourassociated antigens (TAAs), while addressing the challenge of low epitope density
- Understanding the expression threshold – evaluating how TCR affinity and antigen presentation levels impact engagement, efficacy, and safety, with learnings from TCRengineered therapies like tebentafusp
- Pushing beyond monoclonal limits – discussing the role of TCR-mimetics and dualtargeting strategies to improve on-target precision, reduce off-tumour effects, and broaden addressable patient populations